MYGN Relative Valuation
MYGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MYGN is overvalued; if below, it's undervalued.
Historical Valuation
Myriad Genetics Inc (MYGN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -15.60. The fair price of Myriad Genetics Inc (MYGN) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.23
Fair
234.19
PE
1Y
3Y
5Y
Trailing
Forward
21.58
EV/EBITDA
Myriad Genetics Inc. (MYGN) has a current EV/EBITDA of 21.58. The 5-year average EV/EBITDA is 38.87. The thresholds are as follows: Strongly Undervalued below -131.81, Undervalued between -131.81 and -46.47, Fairly Valued between 124.21 and -46.47, Overvalued between 124.21 and 209.55, and Strongly Overvalued above 209.55. The current Forward EV/EBITDA of 21.58 falls within the Historic Trend Line -Fairly Valued range.
78.11
EV/EBIT
Myriad Genetics Inc. (MYGN) has a current EV/EBIT of 78.11. The 5-year average EV/EBIT is -3733.60. The thresholds are as follows: Strongly Undervalued below -36759.14, Undervalued between -36759.14 and -20246.37, Fairly Valued between 12779.17 and -20246.37, Overvalued between 12779.17 and 29291.94, and Strongly Overvalued above 29291.94. The current Forward EV/EBIT of 78.11 falls within the Historic Trend Line -Fairly Valued range.
0.80
PS
Myriad Genetics Inc. (MYGN) has a current PS of 0.80. The 5-year average PS is 2.28. The thresholds are as follows: Strongly Undervalued below 0.46, Undervalued between 0.46 and 1.37, Fairly Valued between 3.19 and 1.37, Overvalued between 3.19 and 4.10, and Strongly Overvalued above 4.10. The current Forward PS of 0.80 falls within the Undervalued range.
30.23
P/OCF
Myriad Genetics Inc. (MYGN) has a current P/OCF of 30.23. The 5-year average P/OCF is 38.51. The thresholds are as follows: Strongly Undervalued below -214.54, Undervalued between -214.54 and -88.02, Fairly Valued between 165.03 and -88.02, Overvalued between 165.03 and 291.56, and Strongly Overvalued above 291.56. The current Forward P/OCF of 30.23 falls within the Historic Trend Line -Fairly Valued range.
-488.04
P/FCF
Myriad Genetics Inc. (MYGN) has a current P/FCF of -488.04. The 5-year average P/FCF is -25.72. The thresholds are as follows: Strongly Undervalued below -423.34, Undervalued between -423.34 and -224.53, Fairly Valued between 173.09 and -224.53, Overvalued between 173.09 and 371.90, and Strongly Overvalued above 371.90. The current Forward P/FCF of -488.04 falls within the Strongly Undervalued range.
Myriad Genetics Inc (MYGN) has a current Price-to-Book (P/B) ratio of 1.83. Compared to its 3-year average P/B ratio of 2.03 , the current P/B ratio is approximately -10.05% higher. Relative to its 5-year average P/B ratio of 2.11, the current P/B ratio is about -13.09% higher. Myriad Genetics Inc (MYGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -7.07%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -5.53% , the current FCF yield is about -100.00% lower.
1.83
P/B
Median3y
2.03
Median5y
2.11
-2.44
FCF Yield
Median3y
-7.07
Median5y
-5.53
Competitors Valuation Multiple
The average P/S ratio for MYGN's competitors is , providing a benchmark for relative valuation. Myriad Genetics Inc Corp (MYGN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -3.56%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MYGN decreased by 46.54% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -10.36 to -13.32.
The secondary factor is the Revenue Growth, contributed -3.56%to the performance.
Overall, the performance of MYGN in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Myriad Genetics Inc (MYGN) currently overvalued or undervalued?
What is Myriad Genetics Inc (MYGN) fair value?
How does MYGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Myriad Genetics Inc (MYGN) as of Dec 05 2025?
What is the current FCF Yield for Myriad Genetics Inc (MYGN) as of Dec 05 2025?
What is the current Forward P/E ratio for Myriad Genetics Inc (MYGN) as of Dec 05 2025?